JPH0467150B2 - - Google Patents
Info
- Publication number
- JPH0467150B2 JPH0467150B2 JP58000084A JP8483A JPH0467150B2 JP H0467150 B2 JPH0467150 B2 JP H0467150B2 JP 58000084 A JP58000084 A JP 58000084A JP 8483 A JP8483 A JP 8483A JP H0467150 B2 JPH0467150 B2 JP H0467150B2
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fragment
- reaction mixture
- component
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012634 fragment Substances 0.000 claims description 101
- 108060003951 Immunoglobulin Proteins 0.000 claims description 36
- 102000018358 immunoglobulin Human genes 0.000 claims description 36
- 210000002966 serum Anatomy 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 14
- 239000011541 reaction mixture Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 8
- 239000013060 biological fluid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims 2
- 230000004931 aggregating effect Effects 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 23
- 241000894007 species Species 0.000 description 15
- 239000004816 latex Substances 0.000 description 9
- 229920000126 latex Polymers 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 238000007818 agglutination assay Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 102000053391 human F Human genes 0.000 description 3
- 108700031895 human F Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Description
æ¬çºæã¯å
ç«æ€å®æ³ã«é¢ãããããã«è©³ããã¯
æ¬çºæã¯å ç«ã°ãããªã³ã®æçã䜿çšããå ç«æ€
å®æ³ã«é¢ããã æ¬çºæè ãã¯ãã®è±åœç¹èš±åºé¡ç¬¬2013211Aå·
æ现æžã«ãããŠãäœæ¶²äžã®æåïŒãã®çšèªã«ã¯ã
ããã³ãå«ãïŒããã®æåã«å¯ŸããŠç¹ç°çãªå ç«
ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçãšåå¿ããããã®éå
å¿ã¯ïŒå šïŒå ç«ã°ãããªã³ããã³ãã®ïŒŠ(c)æçã®
å®è³ªçäžåšã«ãããŠè¡ãªãããšããæãå ç«æ€å®
æ³ã«ã€ããŠèšèŒããã詳现ã¯åèšæ现æžãåç §ã
ã¹ãã§ããããå šå ç«ã°ãããªã³ã®ä»£ãã«ïŒãã
ãŠïŒŠ(c)æçã®äžåšã«ãããŠïŒïŒŠïŒabâ²ïŒ2æçã䜿çš
ããäž»èŠãªç®çããã³å©ç¹ã¯ãæ€å®ã«ãããŠãã
ãããããè¡æž äžã«ååšããããšã®ãããªãŠãã
æ§å åïŒRFïŒããã³c1gïŒè£äœã®æåïŒã«ããå¹²
æžãé²æ¢ããããšã§ããã åèšã®æ¹æ³ã¯ç¹ã«ç²ååéæ€å®ã«ãããŠæçšã§
ããããæ€å®ãç¹ã«ããè¡æž ã®æ€å®ã«ãããŠã¯ä»
ã®çš®é¡ã®å¹²æžãçãåŸããäŸãã°éç¹ç°çç²åå
éãäžè¬çã«è¡æž ã¿ã³ãã¯ã®ååšã«ãã€ãŠçãã
ããšããããæ¬çºæè ãã¯ãããé µçŽ çæ¶åäœçš
ã«ãã€ãŠå æããæ¹æ³ãèšèŒããïŒæ¬çºæè ãã®
ãšãŒãããç¹èš±ç¬¬51985å·æ现æžåç §ïŒãäžè¬ã®è¡
æž ã¿ã³ãã¯ã«ããå¹²æžé²æ¢ã®ããã®é µçŽ çæ¶åäœ
çšã®äœ¿çšã¯ãæ€å®ãã¹ãæåïŒãŸãã¯ãã®æåã®
æå®æçâãšãŒãããç¹èš±ç¬¬51985å·æ现æžïŒã
é µçŽ ã«å¯ŸããŠå®å®ãªå Žåã«ã®ã¿ãäŸãã°ããã·ã³
ãé µçŽ ãšããŠäœ¿ãå Žåã¯ãããã·ã³ãŸãã¯ããã²
ã¹ããã³ã®ãããªæåã«å¯Ÿããæ€å®ã«ãããŠã®
ã¿ãå®æœå¯èœã§ãããè¡æž ã¿ã³ãã¯ã«ããå¹²æžã
æžå°ãŸãã¯é²æ¢ããå¥ã®æ¹æ³ãšããŠã¯ã±ã€ãªãã
ããã¯å€ïŒchaotropic agentïŒã䜿çšããæ¹æ³ã
ããïŒæ¬çºæè ãã¯ãšãŒãããç¹èš±ç¬¬38181å·æ
现æžåç §ïŒããã®æ¹æ³ã¯ã²ããå¿çšãåŸããã®ã§
ãããæ¯èŒçåéåã®åŒ±ãå Žåã«éããããã®ã
ãæ€å®ã®ç²ŸåºŠãäœããªãåŸãã åšç¥ã®éãå ç«æ€å®ã®æè¡ã«ãããŠã¯æè¡æž
ïŒæ€å®ãã¹ãç¹å®ã®æåã«å¯ŸããïŒãåç©æºãã
ååŸããã®ãåžžæ³ã§ãã€ãŠãæãæ®éã®äŸçµŠæºã¯
ãŠãµã®ãã€ã®ããã³ãããžã§ãããåç©æºããã®
æäœã䜿çšããããè¡æž äžã®ææºã®æ€å®ã«ãããŠ
ã¯ãæ£è ã®äžã«ã¯åç©å ç«ã°ãããªã³ã«å¯Ÿããæ
äœãæã€è ããããããå¹²æžãçããããšããã°
ãã°ããããã®åé¡ãåŠçããã®ã«ãããè¡æž ã«
倧éã®åç©å ç«ã°ãããªã³ïŒãã æ€å®ãã¹ãææº
ã«å¯ŸããŠç¹ç°çã§ãªããã®ïŒãå ããããã«ãã
ããè¡æž äžã«ååšããŠåŸããåç©å ç«ã°ãããªã³
ãšåå¿æ§ã®æäœãåå¿ããããã®åŸã®æ€å®ã«ãã
ãŠå¹²æžãçãåŸãªãããã«ããããšã¯ç¥ãããŠã
ãã æ¬çºæè ãã¯ãç²ååéæ€å®ã«ãããå¹²æžé²æ¢
ã®ããã«åèšã®äºé²ãè¡ãªã€ãå Žåã§ããããçš®
ã®æ€å®ã«ãããŠïŒâïŒïŒ ãã®è¡æž ã«ã€ããŠåŸãã
ãçµæã®èª€å·®ãéåžžã«å€§ããããšãèŠãã ããã
çºæè ã¯éæç 究ã®çµæããã®èª€å·®ãåŸæ¥ç¥ãã
ãŠããªããããŠå šãäºæãããªãã€ãäºå®ã«ãã
ããšãç¥ã€ããããªãã¡ããè¡æž ã®ãããã®ã¯ã
åç©ïŒãã以å€ïŒã®å šå ç«ã°ãããªã³ãšã¯åå¿æ§
ããªãããã®ïŒŠïŒabâ²ïŒ2æçãšã¯åå¿æ§ãããæäœ
ãå«ãããšãããäºå®ãèŠãã ãããåŸæ¥ã¯ãã
ãç¹å®ã®çš®ã®äžã§ã¯ãïŒabâ²ïŒ2æçãšã®åå¿ãã
ãå šå ç«ã°ãããªã³ãšã¯åå¿ããªãæäœãååšã
åŸãããšãç¥ãããŠãããããããã®å¹æã¯åäž
ã®çš®ã®äžã§ã®ã¿èµ·ãå šãç°ãªãäºã€ã®çš®ã®éã§ã¯
èµ·ãåŸãªããšåžžã«ä¿¡ããããŠããïŒäŸãã°ãM.
WallerãAmerican Journal of Medicineã54
å·»ã1973幎ïŒæã731ããŒãžåç §ïŒã®ã§ãå®ã«é©
ãã¹ãããšã§ããã ããã«æ¬çºæè ãã¯ãæ€å®ãã¹ãçç©äœæ¶²ïŒäŸ
ãã°ããè¡æž ïŒæºãšãªãç°ãªãçš®ã®åç©æºããå°
ããïŒabâ²ïŒ2æçã䜿çšããæ€å®ã«ãããŠãåèš
ã®å¹æã«ãã誀差ãçãåŸãããšã確ããã ããã«ãŸããããè¡æž äžã«ãã以å€ã®ïŒŠïŒabâ²ïŒ2
æçãšåå¿ããæäœãå«ãŸããŠãããšãã¯ããã
ãã®æäœã¯ãŸãïŒåŒ±ãã§ã¯ãããïŒä»ã®ïŒãã以
å€ã®ïŒå ç«ã°ãããªã³ã®Fabæçãšãåå¿ããã
ã®ã®ããã§ãããåŸã€ãŠäžè¬ã«ãæäœã®ïŒIgâã
ã€ãã¹âFcïŒæçïŒIgã¯å ç«ã°ãããªã³ãæå³
ããïŒã䜿çšããå ç«æ€å®ã¯ãç°çš®ã®åç©ããã®
ããã«å¯Ÿããæäœãšã®åå¿ã®å¯èœæ§ãããããã«
å¹²æžãèµ·ãåŸãããšãããããïŒIgâãã€ãã¹â
FcïŒæäœæçã䜿çšããå ç«æ€å®ã«ãããŠçã
åŸãå¹²æžã®ãã®åå ã¯ãåèšã®éããã®çš®é¡ã®ç°
çš®éçžäºäœçšã¯æ±ºããŠçããªããã®ãšèããããŠ
ããã®ã§ãåŸæ¥ã¯å šãæ°ã¥ãããŠããªãã€ãã åŸã€ãŠæ¬çºæã¯ã第äžã®åç©çš®ããã®çç©äœæ¶²
äžã®å ç«åãå ç«æ€å®ããã«ããããæ€å®åå¿æ··
åç©äžã®åèšè¢«æ€å®å ç«åæåã«å¯ŸããŠå ç«çã«
ç¹ç°çã§ããã第äºã®åç©çš®ããã®å ç«ã°ãããª
ã³ã®ãã¡ããã®å®å šäœïŒå šå ç«ã°ãããªã³ïŒãã
ã³ãã®ïŒŠ(c)æçã®äžåšäžã«ããã®ïŒIgâãã€ãã¹
âFcïŒæçïŒä»¥äžç¹ç°çæçãšç§°ããïŒãåå¿
äœãšããŠäœ¿ãæ¹æ³ã«ãããŠã åèšç¬¬äžã®åç©çš®ã®çç©äœæ¶²äžã«ååšããåèš
ç¹ç°çæçã«å¯ŸããŠåå¿ãã第äžã®åç©çš®ã®æäœ
ãšãåèšç¹ç°çæçãšã®åå¿ã«ãããæ€å®ãžã®å¹²
æžãé²æ¢ãŸãã¯æžå°ãããå·¥çšãå«ãå ç«æ€å®æ³
ãæäŸãããã®ã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã䜿çšãããç¹ç°çæ
çãã¯åå¿æ··åç©ã®è¢«æ€å®æåã«å¯ŸããŠå ç«çã«
ç¹ç°çã§ããå ç«ã°ãããªã³ïŒéåžžIgGã§ããã
å¿ ãããããã«éããªãïŒããå°ããããåŸã€ãŠ
äŸãã°ãã®æçã¯æ€å®ãã¹ãå ç«åã«å¯Ÿãå ç«ç
ã«ç¹ç°çã§ãã€ãŠããããšçŽæ¥åå¿ãããã®ã§ã
ã€ãŠãããããããã¯ãŸãããã®æçã¯åå¿æ··å
ç©äžã®å¥ã®æåãäŸãã°ãå ç«åã«å¿ããéã§ç
æããããŸãã¯ååšããæåã«å¯Ÿãç¹ç°çã§ãã€
ãŠããããåŸã€ãŠå ç«åã¯æçãšçŽæ¥åå¿ããã®
ã§ãªãéæ¥çã«æ€åºãŸãã¯å®éããããã®ã§ãã€
ãŠãããã 奜ãŸããïŒIgâãã€ãã¹âFcïŒæçã¯IgGã®ïŒŠ
ïŒabâ²ïŒ2æçã§ãããããã®åéã«ãããŠåšç¥ã®é
ããä»ã®æçäŸãã°Fabâ²ãŸãã¯FabæçãïŒIgG
以å€ã®å ç«ã°ãããªã³ããã®æçãåæ§ïŒå ç«æ€
å®ã«ãããŠå šå ç«ã°ãããªã³ã®ä»£ãã«ãæã«äœ¿çš
ããããšãã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã¯ããç¹ç°çæçããšè¢«
æ€å®è©Šæäžã®ç¬¬äžã®çš®ã®ããã«å¯ŸããæäœïŒãã
ã¯æ¬è³ªçã«IgMã§ãããïŒãšã®éã®åå¿ã«ãã€ãŠ
çããå¹²æžã¯é²æ¢ãŸãã¯å°ããšãå®è³ªçã«æžå°ã
ãããããè¡ãªãã«ã¯æ°çš®ã®æ¹æ³ããããæ¬çºæ
ã«ãããŠå¥œãŸããæ¹æ³ã¯ãããèªäœã¯æ€å®ã«ãã
ãŠå šãå¹²æžãçããã第äžã®çš®ã®å¹²æžæ§æäœãéž
æçã«äžæŽ»æ§åããäžçš®ä»¥äžã®ç©è³ªã§è¢«æ€å®è©Šæ
ãåŠçããããšã§ãããåçºæã®ããããŠå¥œãŸã
ãç¹åŸŽã«ããã°ãããçš®ã®ïŒIgâãã€ãã¹âFcïŒ
æçã奜ãŸããã¯ããã§ãéç¹ç°çæçããšç§°ã
ãïŒabâ²ïŒ2æçããã®ç®çã«äœ¿çšãããããéç¹
ç°çæçããšãç¹ç°çæçããšã®åºå¥ã¯æ¬¡ã®éã
ã§ããã ãç¹ç°çæçãã¯æ€å®ãã¹ã第äžã®åç©çš®ã®å
ç«åïŒãŸãã¯åå¿æ··åç©ã®ä»ã®æåïŒãšãã第äž
ã®åç©çš®ã®ããïŒãç¹ç°çæçãïŒã«å¯Ÿããæäœ
ïŒãã®æäœã®ååšã«ãã€ãŠå¹²æžãçããïŒãšãå
å¿ããããšã®ã§ãã第äºã®åç©çš®ã®ïŒIgâãã€ã
ã¹âFcïŒæçã§ããïŒ ãéç¹ç°çæçãã¯åèšå ç«åãšã¯åå¿ã§ããª
ãã第äžã®åç©çš®ã®åèšæäœãšã¯åå¿ããããšã®
ã§ãã第äºã®çš®ã®ïŒIgâãã€ãã¹âFcïŒæçã§
ããã åŸã€ãŠãæ€å®ãã¹ãè©Šæããéç¹ç°çæçãã§
åŠçããããšã«ãã€ãŠãè©Šæäžã«ååšããã第äº
ã®çš®ã®æçã«å¯Ÿãã第äžã®åç©çš®ã®åèšæäœã¯ã
ã®ãéç¹ç°çæçããšçµåããããæ€å®æã«ãç¹
ç°çæçããšåå¿ããŠå¹²æžãèµ·ãããšãã§ããªã
ãªãã åšç¥ã®ããã«ãïŒabâ²ïŒ2æçã¯äºäŸ¡ã®å ç«ã°ã
ããªã³æçã§ãããããããããã«å¯Ÿãã第äžã®
çš®ã®æäœã®ãããã®ã¯äºäŸ¡ïŒããªãã¡IgGïŒã§ã
ãããäžéšã¯ç¢ºãã«å€äŸ¡ïŒIgMïŒã§ãããããé
ç¹ç°çæçããšç§°ãã第äžã®çš®ã®æäœãšã®éã®çµ
åå¹çãæ¹åããããã«ã¯ãåéããããéç¹ç°
çæçãã䜿çšããæ¹ã奜ãŸããããšããã®ã¯åŸ
è ã¯å€äŸ¡ã§ãã€ãŠããã«å¯ŸããIgMæäœã®çµåå¹
çããã倧ããããã§ããã ãéç¹ç°çæçãã¯ç±ã«ããããŸãã¯ååŠçã«
åéãããããšãã§ããã©ã¡ãã®å Žåãç·©è¡æ¶²ã«
å¯æº¶ã§ãããç±åéäœã¯é«åºŠåžéæã«ãé·æéã§
ã¯äžå®å®ã§ããã®ã§ååŠçã«åéãããéç¹ç°ç
æçãã䜿çšããæ¹ã奜ãŸãããç±åéããã³å
åŠçåéæçã®èª¿è£œã¯ããããåœæ¥çã«ãããŠå ¬
ç¥ã§ããæç®ã«èšèŒãããŠããã åéããéç¹ç°çæçã®äœ¿çšãããããŠå¥œãŸã
ããããã®ä»£ããã«éç¹ç°çæçãäŸãã°åºåœ¢äž
溶æ§æ¯æäœãŸãã¯å¯æº¶æ§ç©è³ªäŸãã°ã¿ã³ãã¯ãšçµ
åãããããšãå¯èœã§ãããé©åœãªåºåœ¢æ¯æäœãš
ããŠã¯äŸãã°ããªãšã¹ãã¬ã³ãã»ãã¢ããŒã¹ãŸã
ã¯ããªã¢ã¯ãªã«ã¢ãããæããããã æ¬çºæã®æ¹æ³ãéç¹ç°çæçã䜿çšããŠè¡ãªã
ãšãã¯ããç¹ç°çæçããšåäžã®åç©æºããåŸã
ããšã奜ãŸãããäŸãã°éç¹ç°çæçã奜ãŸãã
ã¯å ç«ãããŠããªããŠãã®ããåŸã次ã«ãã®ãŠãµ
ã®ãå ç«ããŠç¹ç°çæçãåŸãããããå®éã«ã¯
äŸãã°å ç«å šã®ãŠãµã®ãšå ç«åŸã®ãŠãµã®ããæ¡ã€
ãè¡æ¶²è©Šæã混泚ããŠæçãåŸãã®ãæè¯ã§ã
ãããã®æäœã«ãããããç¹å®ã®åç©åäœããã®
éç¹ç°çæçã第äžã®çš®ïŒéåžžãããïŒã®æäœã«
察ããŠïŒæ£åžžãããïŒåå¿æ§ã匱ãå Žåã«çãåŸ
ãåé¡ãé²æ¢ããããšãã§ããã åèšã®ããã«æ¬çºæã«ãããŠã¯ãéç¹ç°çæ
çãã®äœ¿çšãããããŠå¥œãŸããããããã ãã«é
å®ããããã®ã§ã¯ãªãã第äžã®çš®ã®æäœãšãç¹ç°
çæçããšã®åå¿ã«ãã€ãŠçããå¹²æžãé€å»ãŸã
ã¯æžå°ããããã«ãåèšæäœãéžæçã«äžæŽ»æ§å
ãããè©Šæããé€å»ããããšãã§ãããããªãã®
ä»ã®ç©è³ªãŸãã¯æè¡ãäŸãã°ã±ã€ãªããããã¯å€
ã®äœ¿çšãé µçŽ çæ¶åãŸãã¯ãžã¹ã«ãã€ãæ©ã®éå
ã«ããIgMæïŒabâ²ïŒ2æäœã®ç Žå£çãå«ããä»ã®
è©Šè¬ãŸãã¯æè¡ã䜿çšããããšãã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã奜ãŸãããéç¹ç°çæ
çãã䜿çšããå ·äœçæ¹æ³ã¯çš®çš®ã§ãã€ãŠããã
äŸãã°ãåéããããéç¹ç°çæçããåã«çç©
äœæ¶²ãšæ··åããŠãæ€å®äžã®æ¶²äœäžã«æ®ããŠãã
ãããŸãé€å»ããŠããããããããã¯å¥œãŸãããª
ããå¥ã®æ¹æ³ãšããŠã¯æ€å®åã«çç©äœæ¶²ãåéã
ãããéç¹ç°çæçããšããŸãã¯äŸãã°åºçžæ¯æ
äœäžã«åºå®ãããéç¹ç°çæçããšæ¥è§ŠãããŠäº
ååŠçããããšã§ãããäŸãã°ãã®ãããªææã
ã€ããã«ã©ã ã䜿çšããããšãã§ããã æ¬çºæã®æ¹æ³ã¯ç²ååéæ€å®æ³ã«æçšã§ã¯ãã
ããïŒIgâãã€ãã¹âFcïŒæçãåå¿äœãšããŠäœ¿
çšããä»ã®å ç«æ€å®ã«ã䜿çšããããšãã§ããäŸ
ãšããŠæ¬çºæè ãã®è±åœç¹èš±ç¬¬2013211Aå·ãã
ã³2045431Aå·æ现æžããã³ç±³åœç¹èš±ç¬¬4184849å·
æ现æžãæããããããããã®å Žåãæ¬æ¹æ³ãæ
åçã«ãããŸãã¯èªåé£ç¶çãŸãã¯åé£ç¶çã«ã
å®æœããããšãã§ããã 奜ãŸããç²ååéæ€å®æ³ã«ãããŠã¯ãæåã®æ€
å®ã¯ãç¹ç°çæçããæ æãã埮现ã«åæ£ããã©
ããã¯ã¹åŸåãšæåãšãæ··åããããšã«ãã€ãŠè¡
ãªããããæåã®ååšéã«å¿ããçšåºŠã®ç²ååé
ãèµ·ããåéããã«æ®ã€ãç²åæ°ãæ°ããããšã«
ããæåã®ååšéã枬å®ã§ããããã®äžè¬çæ¹æ³
ã¯ãçš®ã ã«æ¹å€ãåŸãããåœæ¥çã«ãããŠåšç¥ã§
ããã®ã§ãã以äžã¯èšèŒããªãã æ¬çºæã®æ¹æ³ã¯ïŒç²ååéæ€å®ã«é©çšããã«ã
ãä»ã®æ€å®ã«é©çšããã«ããïŒå ç«åäžè¬ã®æ€å®
ã«åºãé©çšããããšãã§ãããæ¬æ¹æ³ã¯ããè¡æž
äžã®ã¢ã«ãã¢ããšãã¿ã³ãã¯ãããšãªãã³ããã
èç€ã©ã¯ãã²ã³ããããã·ã³çµåã°ãããªã³ã®æ€
å®ããã³ã匷ãã±ã€ãªããããã¯å€ã䜿çšãããš
æåã®æžè¡°ãçãããããªçš®ã ã®ç©è³ªã®æ€å®ã«ã
ããŠç¹ã«æçšã§ããããã®ãããªç©è³ªãšãŠããŠã¯
åºæ¿ãã«ã¢ã³ïŒç²ç¶è ºåºæ¿ããã³åµèåºæ¿ãã«ã¢
ã³çãïŒé žçŽ ïŒé žæ§ãã¹ãã¿ãŒãŒïŒããã³ããçš®
ã®å€§åãŠã€ã«ã¹æåãæããããã æ¬çºæãããã«å®å šã«ç解ã§ããããã«ããã
ããäŸãšããŠæ¬¡ã®å®éšçµæã瀺ãã ïŒ åéããŠãµã®ã®ïŒ£ïŒabâ²ïŒ2 (a) ãŠãµã®ã®ïŒŠïŒabâ²ïŒ2æçæ¬çºæè ãã®è±åœç¹
蚱第2013211Aå·æ现æžã®èšèŒãšåæ§ã«ããŠ
åŸãã (b) ç±åéæçã¯åã«30åé63âã§å ç±ããã
ãšã«ãã€ãŠèª¿è£œããã (c) ååŠçåéæçã¯æ¬¡ã®ããã«ããŠèª¿è£œã
ãïŒéçé žå¡©ç·©è¡æ¶²ïŒ0.1N NaHCO3ãPH
8.8ïŒäžã«ïŒŠïŒabâ²ïŒ2ïŒãŠãµã®ïŒïŒâ10mgïŒmlã
å«æãã溶液ã«ã°ã«ã¿ã«ã¢ã«ãããã®25ïŒ æº¶
液ãå ãæçµåå¿æåæ¿åºŠã0.5ïŒ ãšããã
æ··åç©ã宀枩ïŒçŽ25âïŒã«30åéãããŸããª
ããä¿æž©ã次ã«ç容éã®2.5ïŒ ãšã¿ããŒã«ã¢
ãã³ïŒPH8.5ïŒãå ããŠåå¿ãåæ¢ããã次
ã«æ··åç©ãã°ãªã·ã³âç·©è¡å¡©æ¶²ïŒGBSïŒã«
察ããŠååã«éæããåŸãããåéãã
ïŒabâ²ïŒ2ãã混泚æ£åžžãŠãµã®è¡æž 10ïŒ ãå«æã
ãã°ã«ã·ã³âç·©è¡å¡©æ¶²ã«åžéããåéãã
ïŒabâ²ïŒ2æ¿åºŠ0.1mgïŒmlãšãããæ€å®çšã®è¡æž
ã¯äžèšæ··åç©äžã«ïŒïŒ10ã«åžéããã ïŒ ïŒŠïŒabâ²ïŒ2æçã䜿çšããæ€å®ã«ãããŠã第äº
ã®çš®ïŒãã®å ŽåãŠãµã®ïŒã®æçãšç¬¬äžã®çš®ïŒã
ã®å ŽåããïŒã®ããã«å¯Ÿããæäœãšã®éã®çžäº
äœçšã«ããå¹²æžãèµ·ãããšã瀺ãããã«ãã¢ã«
ãã¢ããšãã¿ã³ãã¯ã®æž¬å®çšã«éçºããæ€å®æ³
ã䜿çšããŠæ¬¡ã®è©Šéšãè¡ãªã€ãããŠãã®ã®æã
ãâã¢ã«ãã¢ããšãã¿ã³ãã¯å ç«ã°ãããªã³ã
åŠçããŠãã®ïŒŠïŒabâ²ïŒ2æçïŒãç¹ç°çæçãïŒã
調補ããããŸãããéç¹ç°çæçãã§è¢«èŠãã
ã©ããã¯ã¹ç²åãã¢ã«ãã¢ããšãã¿ã³ãã¯ã®äž
åšã«ãããŠåéãããè¡æž ãèå¥ããããã«çŽ
200ã®è¡æž ãäºåæ€æ»ããããã®ç®çã®ããã
éå ç«ãŠãµã®ããïŒabâ²ïŒ2æçïŒããªãã¡ãé
ç¹ç°çæçãïŒã調補ããããããå ç«ãããŠ
ãµã®ããã®è¡æž ã䜿çšããã©ããã¯ã¹ã®æšæºç
ãªèª¿è£œã«ãããã®ãšåæ§ãªæ¹æ³ã§åéãã©ãã
ã¯ã¹ã«å ±æçµåçã«çµåããããåŸæ¥æè¡ã®ç¥
èŠã«ããã°ããã®ãããªã©ããã¯ã¹ã¯RFãŸã
ã¯C1qã®ååšã«ãããŠãè¡æž äžã§åéãããšã¯
äºæ³ãããªãã€ããçµæã第ïŒå³ã«ç€ºããå³ã«
ã¯16ã®è¡æž ã®ããã ãã«ã€ããŠïŒçš®ã®ç²åèšæ°
å€ã瀺ãããŠãããããã16ã®è¡æž ã¯å¹²æžãã
ããããšã瀺ãããã®ã§ãããå³ã«ãããŠåè©Š
æã«ã¯çªå·ãä»ããŠãããåè©Šæã«ã€ãç²åä¿
æ°ã¯æ¬¡ã®ããã«è¡ãªã€ãïŒå·Šããäžçªç®ã®æ±ç¶
å³ïŒãéç¹ç°çæçããæ æããã©ããã¯ã¹ç²
åã0.27M BSAïŒGBSïŒBSAã¯ãŠã·è¡æž ã¢ã«
ããã³ãæå³ããïŒã®è¡æž ãšæ··åãããšãã®èš
æ°å€ã å·Šããäºçªç®ã®æ±ç¶å³ïŒæ£åžžãŠãµã®è¡æž
ïŒNRSïŒããå«ãå Žåã®èšç®å€ã å·Šããäžçªç®ã®æ±ç¶å³ïŒãéç¹ç°çæçãã
æ æããã©ããã¯ã¹ç²åãè¡æž ïŒ0.27M
BSAïŒGBSäžïŒãšæ··åããåéãããéç¹ç°
çæçããå ããå Žåã®èšæ°å€ã å³ããäžçªç®ã®æ±ç¶å³ïŒå·Šããäžçªç®ã®æ±ç¶
å³ã®å Žåã«ããã«æ£åžžãŠãµã®è¡æž ãå«ããå Žå
ã®èšæ°å€ã èšæ°ãããã®ã¯éåéç²åã§ããã®ã§ãç²å
èšæ°å€ã倧ããçšå¹²æžãå°ãããšãæå³ããã 第ïŒå³ã«ç€ºãããã«16åã®è¡æž ã¯éåžžã«åé
ã®èãããã®ïŒNo.51ã76ïŒãã軜ããã®ïŒNo.
43ã146ïŒãŸã§çš®ã ã®çšåºŠã®åéã瀺ããïŒã
ãããã®çªå·ã®å·Šããäžçªç®ã®æ±ç¶å³ïŒãå·Šã
ãäºçªç®ã®æ±ç¶å³ãããæ£åžžãŠãµã®è¡æž ã®æ·»å
ïŒè©Šæã®10ïŒ ïŒã§çžåœçšåºŠå¹²æžãæžå°ããŠãã
ã®ã¯äžã€ã®è©ŠæïŒNo.76ïŒã ãã§ããããšãäžæ¹
å·Šããäžçªç®ã®æ±ç¶å³ããããŠãµã®ïŒŠïŒabâ²ïŒ2å
éäœïŒ0.1mgïŒmlïŒã®æ·»å ã«ããäºäŸïŒNo.144ã
100ïŒãé€ãå šéšã§å¹²æžãå®è³ªçã«é€ãããŠã
ãããšãèªãããããæ£åžžãŠãµã®è¡æž ã®æ·»å
ïŒå³ããäžçªç®ã®æ±ç¶å³ïŒã§ã¯ã©ã®è¡æž ã«ãã
ãŠãå¹²æžã¯å®å šã«ã¯é€å»ãããªãã åŸã€ãŠããéç¹ç°çæçãã§è¢«èŠãããã©ã
ãã¯ã¹ã¯ïŒããçš®ã®è¡æž äžã§ïŒåéãããã
ãšãããããã®åéã¯æ··åç©äžã«åéããã
ãéç¹ç°çæçããå ããããšã«ãã€ãŠé²æ¢ã§
ããããšãããããæ£åžžãŠãµã®è¡æž ã®æ·»å ã®å¹
æã¯å°ãããããã¯åéãå®éããŠãµã®ã®ïŒŠ
ïŒabâ²ïŒ2æçãšã¯åå¿ããããŠãµã®ã®å šå ç«ã°ã
ããªã³ãšã¯åå¿ããªãïŒããè¡æž äžã®ïŒæäœã«
ãã€ãŠåŒãèµ·ãããããšã瀺ããŠããã ä»ã®çš®ããã®å ç«ã°ãããªã³ããã®å¹²æžã®é€
å»ã«æå¹ãåŠããæ€èšãããããã€ã®ïŒŠ
ïŒabâ²ïŒ2ãããïŒabâ²ïŒ2ïŒåéãããã®ããã³ã
ãŠããªããã®ïŒãåéããããIgGããã³åé
ãããŠãµã®IgGãè©ŠéšãããããIgGããŠãµã®
IgGãïŒåéãããã®ãããŠããªããã®ãïŒã
ãŸãã€ã®ïŒŠïŒabâ²ïŒ2ãå¹²æžãé€å»ããªãã€ããã
ãïŒabâ²ïŒ2ã¯è¥å¹²ã®è¡æž ã«ã¯æå¹ã§ãã€ããã
ä»ã®è¡æž ã«å¯ŸããŠã¯å¹æãèªããããªãã€ãã ïŒ å¹²æžãIgGæäœã«ãããIgMæäœã«ãããã
決å®ãããããéç¹ç°çæçã«ãã€ãŠåŒ·ãå¹²æž
ã瀺ãåèšã®ãã¡ã®äžã€ã®è¡æž ã0.3ïŒ ïœïŒïœ
ã®ãžããªãã¬ã€ããŒã«ïŒDTTïŒã§37âã§10å
éåŠçãIgMãç Žå£ãããã€ã®ã®æããIgMè¡
æž ãå¹²æžã瀺ããã®äžã€ã®è¡æž ã«æ·»å ãããšäž
ã€ã®è¡æž ã®ãã¡äºã€ã¯å¹²æžããªããªã€ãã
DTTåŠçåŸã«å¹²æžããªããªã€ãã®ãšåãäºã€
è¡æž ããã®å®éšã§å¹²æžããªããªã€ããåŸã€ãŠå¹²
æžã¯æããã«IgGããã³IgMã§ãã€ãã ïŒ åéããŠããªãïŒabâ²ïŒ2ã®å¹æãåéããã
ã®ãšæ¯èŒæž¬å®ããããã«ããã«äžã€å®éšãè¡ãª
ã€ããéç¹ç°çæçã«ããåéã瀺ãå ã€ã®è¡
æž ããç±çãŸãã¯ååŠçã«åéããïŒabâ²ïŒ2ã
ãŸãã¯åéããŠããªãéç¹ç°çæççã«ãã€ãŠ
åŠçãããéåéæçã¯åèšã®å ŽåãããïŒâ
ïŒåé«ãæ¿åºŠã«ãããŠå¹²æžãããªãæžå°ããã
ãå®å šã«ã¯ãªããªããªãã€ããååŠçã«åéã
ãéç¹ç°çæçã®æ¹ãç±åéãããã®ãããã
ãã«å¹çãè¯ãå®å®æ§ãããã®ã§å¥œãŸããã ïŒ æ¬çºæã®æ¹æ³ãç²ååéæ€å®ã«ãããŠããã«
説æãããããçŽ40ã¥ã€ïŒç³»åã®è¡æž ã«ã€ããŠ
ã¢ã«ãã¢ããšãã¿ã³ãã¯ã®åæãè¡ãªã€ããçµ
æã第ïŒè¡šã«ç€ºãïŒ (1) 第ïŒæ¬ã¯â³ãã€ããããAFPãããâ³
ïŒDinabot AFP KitïŒïŒã¢ãããç 究æïŒã
䜿çšããRIAïŒæŸå°ç·å ç«æ€å®æ³ïŒã«ããã (2) 第ïŒæ¬ã¯ãåéããïŒabâ²ïŒ2äžäœ¿çšã§ãæ£
åžžãŠãµã®è¡æž ãå«æããã°ãªã·ã³ç·©è¡å¡©æº¶æ¶²
ïŒGBSïŒNRSïŒäœ¿çšã®PACIAïŒç²åèšæ°å ç«
æ€å®æ³ã«ããæ€å®è£ 眮ïŒã«ããã (3) 第ïŒæ¬ã¯GBSïŒNRSäžåéïŒabâ²ïŒ2䜿çš
ã®PACIAã«ããã (4) 第ïŒæ¬ã¯éå ç«ãŠãµã®ïŒŠïŒabâ²ïŒ2æ æã©ãã
ã¯ã¹ã䜿çšããèªå·±åéå¹²æžã瀺ãïŒçµæã¯
å¿çæ²ç·ã®äœäžïŒ ã§ç€ºãïŒãç·©è¡æ¶²ã¯åèš(2)
ãšåãã§ããã (5) 第ïŒæ¬ã¯ãåèš(4)ãšåæ§ã§ãããç·©è¡æ¶²äž
ã«ïŒŠïŒabâ²ïŒ2ã䜿çšããã ïŒabâ²ïŒ2åéäœããã¹ãŠã®å¹²æžãå®å šã«é€
å»ã§ããªãã€ãã®ã¯ïŒåã®ã¿ã§ããïŒ210581
â24ãâ27ïŒãèšåºçã«ã¯æ®ãã®å¹²æžã¯éèŠã§
ãªãã 第ïŒå³ã«åéïŒabâ²ïŒ2ã䜿çšããªãéœæ§è¡
æž 30è©Šæã®æ€å®çµæïŒPACIA察RIAïŒã瀺
ãïŒïœïŒ0.97ãïœïŒ0.79xïŒ16.2ïŒããããšæ¯
èŒããããã«åéïŒabâ²ïŒ2ã䜿çšããåãè¡
æž ã®æ€å®çµæã第ïŒå³ã«ç€ºãïŒïœïŒ0.99ãïœ
ïŒ0.85xïŒ0.2ïŒãçžé¢æ§ããã³åŸæã¯æãã
ã«æ¹åãããŠããã ïŒ æ¬çºæãããã«èª¬æãããããåŠåš 第16é±ã®
女åããã®è¡æž 99ã«ã€ããŠã¢ã«ãã¢ããšãã¿ã³
ãã¯ãåæããçµæã第ïŒè¡šã«ç€ºããè¡šäžã«ã
ããŠïŒ æ¬ã¯è©Šæçªå·ã§ããã æ¬ã¯åŠåš æéïŒé±ïŒã§ããã æ¬ã¯æŸå°å ç«æ€å®æ³ã«ãã枬å®ããã¢ã«ãã¢
ããšãã¿ã³ãã¯ã§ããã æ¬ã¯æ¬çºæã«ãããªãäºã€ã®ç²ååéæ€å®
ïŒD.EïŒã®çµæã®å¹³åå€ã§ããã æ¬ã¯ïŒ€ããã³ïŒ¥ãšåæ§ã«ã§ãããæ¬çºæã«åŸ
ã€ãŠåéïŒabâ²ïŒ2æçãå ããŠè¡ãªã€ãäºã€ã®
ç²ååéæ€å®ïŒG.HïŒã®çµæã®å¹³åå€ã§ããã æ¬çºæã«åŸã€ãŠïŒŠïŒabâ²ïŒ2åéäœã䜿çšããã
ãšã«ããæ¹åã¯æ¬¡ã®çµ±èšçæ°å€ã«ãã瀺ãã
ãïŒ RIAã«ããå¹³åå€ ïŒ34.6mgïŒml ïŒabâ²ïŒ2åéäœã䜿çšããPACIAã«ããå¹³å
å€ ïŒ34.6mgïŒml NRSã䜿çšãããïŒabâ²ïŒ2åéäœã䜿çšããª
ãPACIAã«ããå¹³åå€ ïŒ45.6mgïŒml
æ¬çºæã¯å ç«ã°ãããªã³ã®æçã䜿çšããå ç«æ€
å®æ³ã«é¢ããã æ¬çºæè ãã¯ãã®è±åœç¹èš±åºé¡ç¬¬2013211Aå·
æ现æžã«ãããŠãäœæ¶²äžã®æåïŒãã®çšèªã«ã¯ã
ããã³ãå«ãïŒããã®æåã«å¯ŸããŠç¹ç°çãªå ç«
ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçãšåå¿ããããã®éå
å¿ã¯ïŒå šïŒå ç«ã°ãããªã³ããã³ãã®ïŒŠ(c)æçã®
å®è³ªçäžåšã«ãããŠè¡ãªãããšããæãå ç«æ€å®
æ³ã«ã€ããŠèšèŒããã詳现ã¯åèšæ现æžãåç §ã
ã¹ãã§ããããå šå ç«ã°ãããªã³ã®ä»£ãã«ïŒãã
ãŠïŒŠ(c)æçã®äžåšã«ãããŠïŒïŒŠïŒabâ²ïŒ2æçã䜿çš
ããäž»èŠãªç®çããã³å©ç¹ã¯ãæ€å®ã«ãããŠãã
ãããããè¡æž äžã«ååšããããšã®ãããªãŠãã
æ§å åïŒRFïŒããã³c1gïŒè£äœã®æåïŒã«ããå¹²
æžãé²æ¢ããããšã§ããã åèšã®æ¹æ³ã¯ç¹ã«ç²ååéæ€å®ã«ãããŠæçšã§
ããããæ€å®ãç¹ã«ããè¡æž ã®æ€å®ã«ãããŠã¯ä»
ã®çš®é¡ã®å¹²æžãçãåŸããäŸãã°éç¹ç°çç²åå
éãäžè¬çã«è¡æž ã¿ã³ãã¯ã®ååšã«ãã€ãŠçãã
ããšããããæ¬çºæè ãã¯ãããé µçŽ çæ¶åäœçš
ã«ãã€ãŠå æããæ¹æ³ãèšèŒããïŒæ¬çºæè ãã®
ãšãŒãããç¹èš±ç¬¬51985å·æ现æžåç §ïŒãäžè¬ã®è¡
æž ã¿ã³ãã¯ã«ããå¹²æžé²æ¢ã®ããã®é µçŽ çæ¶åäœ
çšã®äœ¿çšã¯ãæ€å®ãã¹ãæåïŒãŸãã¯ãã®æåã®
æå®æçâãšãŒãããç¹èš±ç¬¬51985å·æ现æžïŒã
é µçŽ ã«å¯ŸããŠå®å®ãªå Žåã«ã®ã¿ãäŸãã°ããã·ã³
ãé µçŽ ãšããŠäœ¿ãå Žåã¯ãããã·ã³ãŸãã¯ããã²
ã¹ããã³ã®ãããªæåã«å¯Ÿããæ€å®ã«ãããŠã®
ã¿ãå®æœå¯èœã§ãããè¡æž ã¿ã³ãã¯ã«ããå¹²æžã
æžå°ãŸãã¯é²æ¢ããå¥ã®æ¹æ³ãšããŠã¯ã±ã€ãªãã
ããã¯å€ïŒchaotropic agentïŒã䜿çšããæ¹æ³ã
ããïŒæ¬çºæè ãã¯ãšãŒãããç¹èš±ç¬¬38181å·æ
现æžåç §ïŒããã®æ¹æ³ã¯ã²ããå¿çšãåŸããã®ã§
ãããæ¯èŒçåéåã®åŒ±ãå Žåã«éããããã®ã
ãæ€å®ã®ç²ŸåºŠãäœããªãåŸãã åšç¥ã®éãå ç«æ€å®ã®æè¡ã«ãããŠã¯æè¡æž
ïŒæ€å®ãã¹ãç¹å®ã®æåã«å¯ŸããïŒãåç©æºãã
ååŸããã®ãåžžæ³ã§ãã€ãŠãæãæ®éã®äŸçµŠæºã¯
ãŠãµã®ãã€ã®ããã³ãããžã§ãããåç©æºããã®
æäœã䜿çšããããè¡æž äžã®ææºã®æ€å®ã«ãããŠ
ã¯ãæ£è ã®äžã«ã¯åç©å ç«ã°ãããªã³ã«å¯Ÿããæ
äœãæã€è ããããããå¹²æžãçããããšããã°
ãã°ããããã®åé¡ãåŠçããã®ã«ãããè¡æž ã«
倧éã®åç©å ç«ã°ãããªã³ïŒãã æ€å®ãã¹ãææº
ã«å¯ŸããŠç¹ç°çã§ãªããã®ïŒãå ããããã«ãã
ããè¡æž äžã«ååšããŠåŸããåç©å ç«ã°ãããªã³
ãšåå¿æ§ã®æäœãåå¿ããããã®åŸã®æ€å®ã«ãã
ãŠå¹²æžãçãåŸãªãããã«ããããšã¯ç¥ãããŠã
ãã æ¬çºæè ãã¯ãç²ååéæ€å®ã«ãããå¹²æžé²æ¢
ã®ããã«åèšã®äºé²ãè¡ãªã€ãå Žåã§ããããçš®
ã®æ€å®ã«ãããŠïŒâïŒïŒ ãã®è¡æž ã«ã€ããŠåŸãã
ãçµæã®èª€å·®ãéåžžã«å€§ããããšãèŠãã ããã
çºæè ã¯éæç 究ã®çµæããã®èª€å·®ãåŸæ¥ç¥ãã
ãŠããªããããŠå šãäºæãããªãã€ãäºå®ã«ãã
ããšãç¥ã€ããããªãã¡ããè¡æž ã®ãããã®ã¯ã
åç©ïŒãã以å€ïŒã®å šå ç«ã°ãããªã³ãšã¯åå¿æ§
ããªãããã®ïŒŠïŒabâ²ïŒ2æçãšã¯åå¿æ§ãããæäœ
ãå«ãããšãããäºå®ãèŠãã ãããåŸæ¥ã¯ãã
ãç¹å®ã®çš®ã®äžã§ã¯ãïŒabâ²ïŒ2æçãšã®åå¿ãã
ãå šå ç«ã°ãããªã³ãšã¯åå¿ããªãæäœãååšã
åŸãããšãç¥ãããŠãããããããã®å¹æã¯åäž
ã®çš®ã®äžã§ã®ã¿èµ·ãå šãç°ãªãäºã€ã®çš®ã®éã§ã¯
èµ·ãåŸãªããšåžžã«ä¿¡ããããŠããïŒäŸãã°ãM.
WallerãAmerican Journal of Medicineã54
å·»ã1973幎ïŒæã731ããŒãžåç §ïŒã®ã§ãå®ã«é©
ãã¹ãããšã§ããã ããã«æ¬çºæè ãã¯ãæ€å®ãã¹ãçç©äœæ¶²ïŒäŸ
ãã°ããè¡æž ïŒæºãšãªãç°ãªãçš®ã®åç©æºããå°
ããïŒabâ²ïŒ2æçã䜿çšããæ€å®ã«ãããŠãåèš
ã®å¹æã«ãã誀差ãçãåŸãããšã確ããã ããã«ãŸããããè¡æž äžã«ãã以å€ã®ïŒŠïŒabâ²ïŒ2
æçãšåå¿ããæäœãå«ãŸããŠãããšãã¯ããã
ãã®æäœã¯ãŸãïŒåŒ±ãã§ã¯ãããïŒä»ã®ïŒãã以
å€ã®ïŒå ç«ã°ãããªã³ã®Fabæçãšãåå¿ããã
ã®ã®ããã§ãããåŸã€ãŠäžè¬ã«ãæäœã®ïŒIgâã
ã€ãã¹âFcïŒæçïŒIgã¯å ç«ã°ãããªã³ãæå³
ããïŒã䜿çšããå ç«æ€å®ã¯ãç°çš®ã®åç©ããã®
ããã«å¯Ÿããæäœãšã®åå¿ã®å¯èœæ§ãããããã«
å¹²æžãèµ·ãåŸãããšãããããïŒIgâãã€ãã¹â
FcïŒæäœæçã䜿çšããå ç«æ€å®ã«ãããŠçã
åŸãå¹²æžã®ãã®åå ã¯ãåèšã®éããã®çš®é¡ã®ç°
çš®éçžäºäœçšã¯æ±ºããŠçããªããã®ãšèããããŠ
ããã®ã§ãåŸæ¥ã¯å šãæ°ã¥ãããŠããªãã€ãã åŸã€ãŠæ¬çºæã¯ã第äžã®åç©çš®ããã®çç©äœæ¶²
äžã®å ç«åãå ç«æ€å®ããã«ããããæ€å®åå¿æ··
åç©äžã®åèšè¢«æ€å®å ç«åæåã«å¯ŸããŠå ç«çã«
ç¹ç°çã§ããã第äºã®åç©çš®ããã®å ç«ã°ãããª
ã³ã®ãã¡ããã®å®å šäœïŒå šå ç«ã°ãããªã³ïŒãã
ã³ãã®ïŒŠ(c)æçã®äžåšäžã«ããã®ïŒIgâãã€ãã¹
âFcïŒæçïŒä»¥äžç¹ç°çæçãšç§°ããïŒãåå¿
äœãšããŠäœ¿ãæ¹æ³ã«ãããŠã åèšç¬¬äžã®åç©çš®ã®çç©äœæ¶²äžã«ååšããåèš
ç¹ç°çæçã«å¯ŸããŠåå¿ãã第äžã®åç©çš®ã®æäœ
ãšãåèšç¹ç°çæçãšã®åå¿ã«ãããæ€å®ãžã®å¹²
æžãé²æ¢ãŸãã¯æžå°ãããå·¥çšãå«ãå ç«æ€å®æ³
ãæäŸãããã®ã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã䜿çšãããç¹ç°çæ
çãã¯åå¿æ··åç©ã®è¢«æ€å®æåã«å¯ŸããŠå ç«çã«
ç¹ç°çã§ããå ç«ã°ãããªã³ïŒéåžžIgGã§ããã
å¿ ãããããã«éããªãïŒããå°ããããåŸã€ãŠ
äŸãã°ãã®æçã¯æ€å®ãã¹ãå ç«åã«å¯Ÿãå ç«ç
ã«ç¹ç°çã§ãã€ãŠããããšçŽæ¥åå¿ãããã®ã§ã
ã€ãŠãããããããã¯ãŸãããã®æçã¯åå¿æ··å
ç©äžã®å¥ã®æåãäŸãã°ãå ç«åã«å¿ããéã§ç
æããããŸãã¯ååšããæåã«å¯Ÿãç¹ç°çã§ãã€
ãŠããããåŸã€ãŠå ç«åã¯æçãšçŽæ¥åå¿ããã®
ã§ãªãéæ¥çã«æ€åºãŸãã¯å®éããããã®ã§ãã€
ãŠãããã 奜ãŸããïŒIgâãã€ãã¹âFcïŒæçã¯IgGã®ïŒŠ
ïŒabâ²ïŒ2æçã§ãããããã®åéã«ãããŠåšç¥ã®é
ããä»ã®æçäŸãã°Fabâ²ãŸãã¯FabæçãïŒIgG
以å€ã®å ç«ã°ãããªã³ããã®æçãåæ§ïŒå ç«æ€
å®ã«ãããŠå šå ç«ã°ãããªã³ã®ä»£ãã«ãæã«äœ¿çš
ããããšãã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã¯ããç¹ç°çæçããšè¢«
æ€å®è©Šæäžã®ç¬¬äžã®çš®ã®ããã«å¯ŸããæäœïŒãã
ã¯æ¬è³ªçã«IgMã§ãããïŒãšã®éã®åå¿ã«ãã€ãŠ
çããå¹²æžã¯é²æ¢ãŸãã¯å°ããšãå®è³ªçã«æžå°ã
ãããããè¡ãªãã«ã¯æ°çš®ã®æ¹æ³ããããæ¬çºæ
ã«ãããŠå¥œãŸããæ¹æ³ã¯ãããèªäœã¯æ€å®ã«ãã
ãŠå šãå¹²æžãçããã第äžã®çš®ã®å¹²æžæ§æäœãéž
æçã«äžæŽ»æ§åããäžçš®ä»¥äžã®ç©è³ªã§è¢«æ€å®è©Šæ
ãåŠçããããšã§ãããåçºæã®ããããŠå¥œãŸã
ãç¹åŸŽã«ããã°ãããçš®ã®ïŒIgâãã€ãã¹âFcïŒ
æçã奜ãŸããã¯ããã§ãéç¹ç°çæçããšç§°ã
ãïŒabâ²ïŒ2æçããã®ç®çã«äœ¿çšãããããéç¹
ç°çæçããšãç¹ç°çæçããšã®åºå¥ã¯æ¬¡ã®éã
ã§ããã ãç¹ç°çæçãã¯æ€å®ãã¹ã第äžã®åç©çš®ã®å
ç«åïŒãŸãã¯åå¿æ··åç©ã®ä»ã®æåïŒãšãã第äž
ã®åç©çš®ã®ããïŒãç¹ç°çæçãïŒã«å¯Ÿããæäœ
ïŒãã®æäœã®ååšã«ãã€ãŠå¹²æžãçããïŒãšãå
å¿ããããšã®ã§ãã第äºã®åç©çš®ã®ïŒIgâãã€ã
ã¹âFcïŒæçã§ããïŒ ãéç¹ç°çæçãã¯åèšå ç«åãšã¯åå¿ã§ããª
ãã第äžã®åç©çš®ã®åèšæäœãšã¯åå¿ããããšã®
ã§ãã第äºã®çš®ã®ïŒIgâãã€ãã¹âFcïŒæçã§
ããã åŸã€ãŠãæ€å®ãã¹ãè©Šæããéç¹ç°çæçãã§
åŠçããããšã«ãã€ãŠãè©Šæäžã«ååšããã第äº
ã®çš®ã®æçã«å¯Ÿãã第äžã®åç©çš®ã®åèšæäœã¯ã
ã®ãéç¹ç°çæçããšçµåããããæ€å®æã«ãç¹
ç°çæçããšåå¿ããŠå¹²æžãèµ·ãããšãã§ããªã
ãªãã åšç¥ã®ããã«ãïŒabâ²ïŒ2æçã¯äºäŸ¡ã®å ç«ã°ã
ããªã³æçã§ãããããããããã«å¯Ÿãã第äžã®
çš®ã®æäœã®ãããã®ã¯äºäŸ¡ïŒããªãã¡IgGïŒã§ã
ãããäžéšã¯ç¢ºãã«å€äŸ¡ïŒIgMïŒã§ãããããé
ç¹ç°çæçããšç§°ãã第äžã®çš®ã®æäœãšã®éã®çµ
åå¹çãæ¹åããããã«ã¯ãåéããããéç¹ç°
çæçãã䜿çšããæ¹ã奜ãŸããããšããã®ã¯åŸ
è ã¯å€äŸ¡ã§ãã€ãŠããã«å¯ŸããIgMæäœã®çµåå¹
çããã倧ããããã§ããã ãéç¹ç°çæçãã¯ç±ã«ããããŸãã¯ååŠçã«
åéãããããšãã§ããã©ã¡ãã®å Žåãç·©è¡æ¶²ã«
å¯æº¶ã§ãããç±åéäœã¯é«åºŠåžéæã«ãé·æéã§
ã¯äžå®å®ã§ããã®ã§ååŠçã«åéãããéç¹ç°ç
æçãã䜿çšããæ¹ã奜ãŸãããç±åéããã³å
åŠçåéæçã®èª¿è£œã¯ããããåœæ¥çã«ãããŠå ¬
ç¥ã§ããæç®ã«èšèŒãããŠããã åéããéç¹ç°çæçã®äœ¿çšãããããŠå¥œãŸã
ããããã®ä»£ããã«éç¹ç°çæçãäŸãã°åºåœ¢äž
溶æ§æ¯æäœãŸãã¯å¯æº¶æ§ç©è³ªäŸãã°ã¿ã³ãã¯ãšçµ
åãããããšãå¯èœã§ãããé©åœãªåºåœ¢æ¯æäœãš
ããŠã¯äŸãã°ããªãšã¹ãã¬ã³ãã»ãã¢ããŒã¹ãŸã
ã¯ããªã¢ã¯ãªã«ã¢ãããæããããã æ¬çºæã®æ¹æ³ãéç¹ç°çæçã䜿çšããŠè¡ãªã
ãšãã¯ããç¹ç°çæçããšåäžã®åç©æºããåŸã
ããšã奜ãŸãããäŸãã°éç¹ç°çæçã奜ãŸãã
ã¯å ç«ãããŠããªããŠãã®ããåŸã次ã«ãã®ãŠãµ
ã®ãå ç«ããŠç¹ç°çæçãåŸãããããå®éã«ã¯
äŸãã°å ç«å šã®ãŠãµã®ãšå ç«åŸã®ãŠãµã®ããæ¡ã€
ãè¡æ¶²è©Šæã混泚ããŠæçãåŸãã®ãæè¯ã§ã
ãããã®æäœã«ãããããç¹å®ã®åç©åäœããã®
éç¹ç°çæçã第äžã®çš®ïŒéåžžãããïŒã®æäœã«
察ããŠïŒæ£åžžãããïŒåå¿æ§ã匱ãå Žåã«çãåŸ
ãåé¡ãé²æ¢ããããšãã§ããã åèšã®ããã«æ¬çºæã«ãããŠã¯ãéç¹ç°çæ
çãã®äœ¿çšãããããŠå¥œãŸããããããã ãã«é
å®ããããã®ã§ã¯ãªãã第äžã®çš®ã®æäœãšãç¹ç°
çæçããšã®åå¿ã«ãã€ãŠçããå¹²æžãé€å»ãŸã
ã¯æžå°ããããã«ãåèšæäœãéžæçã«äžæŽ»æ§å
ãããè©Šæããé€å»ããããšãã§ãããããªãã®
ä»ã®ç©è³ªãŸãã¯æè¡ãäŸãã°ã±ã€ãªããããã¯å€
ã®äœ¿çšãé µçŽ çæ¶åãŸãã¯ãžã¹ã«ãã€ãæ©ã®éå
ã«ããIgMæïŒabâ²ïŒ2æäœã®ç Žå£çãå«ããä»ã®
è©Šè¬ãŸãã¯æè¡ã䜿çšããããšãã§ããã æ¬çºæã®æ¹æ³ã«ãããŠã奜ãŸãããéç¹ç°çæ
çãã䜿çšããå ·äœçæ¹æ³ã¯çš®çš®ã§ãã€ãŠããã
äŸãã°ãåéããããéç¹ç°çæçããåã«çç©
äœæ¶²ãšæ··åããŠãæ€å®äžã®æ¶²äœäžã«æ®ããŠãã
ãããŸãé€å»ããŠããããããããã¯å¥œãŸãããª
ããå¥ã®æ¹æ³ãšããŠã¯æ€å®åã«çç©äœæ¶²ãåéã
ãããéç¹ç°çæçããšããŸãã¯äŸãã°åºçžæ¯æ
äœäžã«åºå®ãããéç¹ç°çæçããšæ¥è§ŠãããŠäº
ååŠçããããšã§ãããäŸãã°ãã®ãããªææã
ã€ããã«ã©ã ã䜿çšããããšãã§ããã æ¬çºæã®æ¹æ³ã¯ç²ååéæ€å®æ³ã«æçšã§ã¯ãã
ããïŒIgâãã€ãã¹âFcïŒæçãåå¿äœãšããŠäœ¿
çšããä»ã®å ç«æ€å®ã«ã䜿çšããããšãã§ããäŸ
ãšããŠæ¬çºæè ãã®è±åœç¹èš±ç¬¬2013211Aå·ãã
ã³2045431Aå·æ现æžããã³ç±³åœç¹èš±ç¬¬4184849å·
æ现æžãæããããããããã®å Žåãæ¬æ¹æ³ãæ
åçã«ãããŸãã¯èªåé£ç¶çãŸãã¯åé£ç¶çã«ã
å®æœããããšãã§ããã 奜ãŸããç²ååéæ€å®æ³ã«ãããŠã¯ãæåã®æ€
å®ã¯ãç¹ç°çæçããæ æãã埮现ã«åæ£ããã©
ããã¯ã¹åŸåãšæåãšãæ··åããããšã«ãã€ãŠè¡
ãªããããæåã®ååšéã«å¿ããçšåºŠã®ç²ååé
ãèµ·ããåéããã«æ®ã€ãç²åæ°ãæ°ããããšã«
ããæåã®ååšéã枬å®ã§ããããã®äžè¬çæ¹æ³
ã¯ãçš®ã ã«æ¹å€ãåŸãããåœæ¥çã«ãããŠåšç¥ã§
ããã®ã§ãã以äžã¯èšèŒããªãã æ¬çºæã®æ¹æ³ã¯ïŒç²ååéæ€å®ã«é©çšããã«ã
ãä»ã®æ€å®ã«é©çšããã«ããïŒå ç«åäžè¬ã®æ€å®
ã«åºãé©çšããããšãã§ãããæ¬æ¹æ³ã¯ããè¡æž
äžã®ã¢ã«ãã¢ããšãã¿ã³ãã¯ãããšãªãã³ããã
èç€ã©ã¯ãã²ã³ããããã·ã³çµåã°ãããªã³ã®æ€
å®ããã³ã匷ãã±ã€ãªããããã¯å€ã䜿çšãããš
æåã®æžè¡°ãçãããããªçš®ã ã®ç©è³ªã®æ€å®ã«ã
ããŠç¹ã«æçšã§ããããã®ãããªç©è³ªãšãŠããŠã¯
åºæ¿ãã«ã¢ã³ïŒç²ç¶è ºåºæ¿ããã³åµèåºæ¿ãã«ã¢
ã³çãïŒé žçŽ ïŒé žæ§ãã¹ãã¿ãŒãŒïŒããã³ããçš®
ã®å€§åãŠã€ã«ã¹æåãæããããã æ¬çºæãããã«å®å šã«ç解ã§ããããã«ããã
ããäŸãšããŠæ¬¡ã®å®éšçµæã瀺ãã ïŒ åéããŠãµã®ã®ïŒ£ïŒabâ²ïŒ2 (a) ãŠãµã®ã®ïŒŠïŒabâ²ïŒ2æçæ¬çºæè ãã®è±åœç¹
蚱第2013211Aå·æ现æžã®èšèŒãšåæ§ã«ããŠ
åŸãã (b) ç±åéæçã¯åã«30åé63âã§å ç±ããã
ãšã«ãã€ãŠèª¿è£œããã (c) ååŠçåéæçã¯æ¬¡ã®ããã«ããŠèª¿è£œã
ãïŒéçé žå¡©ç·©è¡æ¶²ïŒ0.1N NaHCO3ãPH
8.8ïŒäžã«ïŒŠïŒabâ²ïŒ2ïŒãŠãµã®ïŒïŒâ10mgïŒmlã
å«æãã溶液ã«ã°ã«ã¿ã«ã¢ã«ãããã®25ïŒ æº¶
液ãå ãæçµåå¿æåæ¿åºŠã0.5ïŒ ãšããã
æ··åç©ã宀枩ïŒçŽ25âïŒã«30åéãããŸããª
ããä¿æž©ã次ã«ç容éã®2.5ïŒ ãšã¿ããŒã«ã¢
ãã³ïŒPH8.5ïŒãå ããŠåå¿ãåæ¢ããã次
ã«æ··åç©ãã°ãªã·ã³âç·©è¡å¡©æ¶²ïŒGBSïŒã«
察ããŠååã«éæããåŸãããåéãã
ïŒabâ²ïŒ2ãã混泚æ£åžžãŠãµã®è¡æž 10ïŒ ãå«æã
ãã°ã«ã·ã³âç·©è¡å¡©æ¶²ã«åžéããåéãã
ïŒabâ²ïŒ2æ¿åºŠ0.1mgïŒmlãšãããæ€å®çšã®è¡æž
ã¯äžèšæ··åç©äžã«ïŒïŒ10ã«åžéããã ïŒ ïŒŠïŒabâ²ïŒ2æçã䜿çšããæ€å®ã«ãããŠã第äº
ã®çš®ïŒãã®å ŽåãŠãµã®ïŒã®æçãšç¬¬äžã®çš®ïŒã
ã®å ŽåããïŒã®ããã«å¯Ÿããæäœãšã®éã®çžäº
äœçšã«ããå¹²æžãèµ·ãããšã瀺ãããã«ãã¢ã«
ãã¢ããšãã¿ã³ãã¯ã®æž¬å®çšã«éçºããæ€å®æ³
ã䜿çšããŠæ¬¡ã®è©Šéšãè¡ãªã€ãããŠãã®ã®æã
ãâã¢ã«ãã¢ããšãã¿ã³ãã¯å ç«ã°ãããªã³ã
åŠçããŠãã®ïŒŠïŒabâ²ïŒ2æçïŒãç¹ç°çæçãïŒã
調補ããããŸãããéç¹ç°çæçãã§è¢«èŠãã
ã©ããã¯ã¹ç²åãã¢ã«ãã¢ããšãã¿ã³ãã¯ã®äž
åšã«ãããŠåéãããè¡æž ãèå¥ããããã«çŽ
200ã®è¡æž ãäºåæ€æ»ããããã®ç®çã®ããã
éå ç«ãŠãµã®ããïŒabâ²ïŒ2æçïŒããªãã¡ãé
ç¹ç°çæçãïŒã調補ããããããå ç«ãããŠ
ãµã®ããã®è¡æž ã䜿çšããã©ããã¯ã¹ã®æšæºç
ãªèª¿è£œã«ãããã®ãšåæ§ãªæ¹æ³ã§åéãã©ãã
ã¯ã¹ã«å ±æçµåçã«çµåããããåŸæ¥æè¡ã®ç¥
èŠã«ããã°ããã®ãããªã©ããã¯ã¹ã¯RFãŸã
ã¯C1qã®ååšã«ãããŠãè¡æž äžã§åéãããšã¯
äºæ³ãããªãã€ããçµæã第ïŒå³ã«ç€ºããå³ã«
ã¯16ã®è¡æž ã®ããã ãã«ã€ããŠïŒçš®ã®ç²åèšæ°
å€ã瀺ãããŠãããããã16ã®è¡æž ã¯å¹²æžãã
ããããšã瀺ãããã®ã§ãããå³ã«ãããŠåè©Š
æã«ã¯çªå·ãä»ããŠãããåè©Šæã«ã€ãç²åä¿
æ°ã¯æ¬¡ã®ããã«è¡ãªã€ãïŒå·Šããäžçªç®ã®æ±ç¶
å³ïŒãéç¹ç°çæçããæ æããã©ããã¯ã¹ç²
åã0.27M BSAïŒGBSïŒBSAã¯ãŠã·è¡æž ã¢ã«
ããã³ãæå³ããïŒã®è¡æž ãšæ··åãããšãã®èš
æ°å€ã å·Šããäºçªç®ã®æ±ç¶å³ïŒæ£åžžãŠãµã®è¡æž
ïŒNRSïŒããå«ãå Žåã®èšç®å€ã å·Šããäžçªç®ã®æ±ç¶å³ïŒãéç¹ç°çæçãã
æ æããã©ããã¯ã¹ç²åãè¡æž ïŒ0.27M
BSAïŒGBSäžïŒãšæ··åããåéãããéç¹ç°
çæçããå ããå Žåã®èšæ°å€ã å³ããäžçªç®ã®æ±ç¶å³ïŒå·Šããäžçªç®ã®æ±ç¶
å³ã®å Žåã«ããã«æ£åžžãŠãµã®è¡æž ãå«ããå Žå
ã®èšæ°å€ã èšæ°ãããã®ã¯éåéç²åã§ããã®ã§ãç²å
èšæ°å€ã倧ããçšå¹²æžãå°ãããšãæå³ããã 第ïŒå³ã«ç€ºãããã«16åã®è¡æž ã¯éåžžã«åé
ã®èãããã®ïŒNo.51ã76ïŒãã軜ããã®ïŒNo.
43ã146ïŒãŸã§çš®ã ã®çšåºŠã®åéã瀺ããïŒã
ãããã®çªå·ã®å·Šããäžçªç®ã®æ±ç¶å³ïŒãå·Šã
ãäºçªç®ã®æ±ç¶å³ãããæ£åžžãŠãµã®è¡æž ã®æ·»å
ïŒè©Šæã®10ïŒ ïŒã§çžåœçšåºŠå¹²æžãæžå°ããŠãã
ã®ã¯äžã€ã®è©ŠæïŒNo.76ïŒã ãã§ããããšãäžæ¹
å·Šããäžçªç®ã®æ±ç¶å³ããããŠãµã®ïŒŠïŒabâ²ïŒ2å
éäœïŒ0.1mgïŒmlïŒã®æ·»å ã«ããäºäŸïŒNo.144ã
100ïŒãé€ãå šéšã§å¹²æžãå®è³ªçã«é€ãããŠã
ãããšãèªãããããæ£åžžãŠãµã®è¡æž ã®æ·»å
ïŒå³ããäžçªç®ã®æ±ç¶å³ïŒã§ã¯ã©ã®è¡æž ã«ãã
ãŠãå¹²æžã¯å®å šã«ã¯é€å»ãããªãã åŸã€ãŠããéç¹ç°çæçãã§è¢«èŠãããã©ã
ãã¯ã¹ã¯ïŒããçš®ã®è¡æž äžã§ïŒåéãããã
ãšãããããã®åéã¯æ··åç©äžã«åéããã
ãéç¹ç°çæçããå ããããšã«ãã€ãŠé²æ¢ã§
ããããšãããããæ£åžžãŠãµã®è¡æž ã®æ·»å ã®å¹
æã¯å°ãããããã¯åéãå®éããŠãµã®ã®ïŒŠ
ïŒabâ²ïŒ2æçãšã¯åå¿ããããŠãµã®ã®å šå ç«ã°ã
ããªã³ãšã¯åå¿ããªãïŒããè¡æž äžã®ïŒæäœã«
ãã€ãŠåŒãèµ·ãããããšã瀺ããŠããã ä»ã®çš®ããã®å ç«ã°ãããªã³ããã®å¹²æžã®é€
å»ã«æå¹ãåŠããæ€èšãããããã€ã®ïŒŠ
ïŒabâ²ïŒ2ãããïŒabâ²ïŒ2ïŒåéãããã®ããã³ã
ãŠããªããã®ïŒãåéããããIgGããã³åé
ãããŠãµã®IgGãè©ŠéšãããããIgGããŠãµã®
IgGãïŒåéãããã®ãããŠããªããã®ãïŒã
ãŸãã€ã®ïŒŠïŒabâ²ïŒ2ãå¹²æžãé€å»ããªãã€ããã
ãïŒabâ²ïŒ2ã¯è¥å¹²ã®è¡æž ã«ã¯æå¹ã§ãã€ããã
ä»ã®è¡æž ã«å¯ŸããŠã¯å¹æãèªããããªãã€ãã ïŒ å¹²æžãIgGæäœã«ãããIgMæäœã«ãããã
決å®ãããããéç¹ç°çæçã«ãã€ãŠåŒ·ãå¹²æž
ã瀺ãåèšã®ãã¡ã®äžã€ã®è¡æž ã0.3ïŒ ïœïŒïœ
ã®ãžããªãã¬ã€ããŒã«ïŒDTTïŒã§37âã§10å
éåŠçãIgMãç Žå£ãããã€ã®ã®æããIgMè¡
æž ãå¹²æžã瀺ããã®äžã€ã®è¡æž ã«æ·»å ãããšäž
ã€ã®è¡æž ã®ãã¡äºã€ã¯å¹²æžããªããªã€ãã
DTTåŠçåŸã«å¹²æžããªããªã€ãã®ãšåãäºã€
è¡æž ããã®å®éšã§å¹²æžããªããªã€ããåŸã€ãŠå¹²
æžã¯æããã«IgGããã³IgMã§ãã€ãã ïŒ åéããŠããªãïŒabâ²ïŒ2ã®å¹æãåéããã
ã®ãšæ¯èŒæž¬å®ããããã«ããã«äžã€å®éšãè¡ãª
ã€ããéç¹ç°çæçã«ããåéã瀺ãå ã€ã®è¡
æž ããç±çãŸãã¯ååŠçã«åéããïŒabâ²ïŒ2ã
ãŸãã¯åéããŠããªãéç¹ç°çæççã«ãã€ãŠ
åŠçãããéåéæçã¯åèšã®å ŽåãããïŒâ
ïŒåé«ãæ¿åºŠã«ãããŠå¹²æžãããªãæžå°ããã
ãå®å šã«ã¯ãªããªããªãã€ããååŠçã«åéã
ãéç¹ç°çæçã®æ¹ãç±åéãããã®ãããã
ãã«å¹çãè¯ãå®å®æ§ãããã®ã§å¥œãŸããã ïŒ æ¬çºæã®æ¹æ³ãç²ååéæ€å®ã«ãããŠããã«
説æãããããçŽ40ã¥ã€ïŒç³»åã®è¡æž ã«ã€ããŠ
ã¢ã«ãã¢ããšãã¿ã³ãã¯ã®åæãè¡ãªã€ããçµ
æã第ïŒè¡šã«ç€ºãïŒ (1) 第ïŒæ¬ã¯â³ãã€ããããAFPãããâ³
ïŒDinabot AFP KitïŒïŒã¢ãããç 究æïŒã
䜿çšããRIAïŒæŸå°ç·å ç«æ€å®æ³ïŒã«ããã (2) 第ïŒæ¬ã¯ãåéããïŒabâ²ïŒ2äžäœ¿çšã§ãæ£
åžžãŠãµã®è¡æž ãå«æããã°ãªã·ã³ç·©è¡å¡©æº¶æ¶²
ïŒGBSïŒNRSïŒäœ¿çšã®PACIAïŒç²åèšæ°å ç«
æ€å®æ³ã«ããæ€å®è£ 眮ïŒã«ããã (3) 第ïŒæ¬ã¯GBSïŒNRSäžåéïŒabâ²ïŒ2䜿çš
ã®PACIAã«ããã (4) 第ïŒæ¬ã¯éå ç«ãŠãµã®ïŒŠïŒabâ²ïŒ2æ æã©ãã
ã¯ã¹ã䜿çšããèªå·±åéå¹²æžã瀺ãïŒçµæã¯
å¿çæ²ç·ã®äœäžïŒ ã§ç€ºãïŒãç·©è¡æ¶²ã¯åèš(2)
ãšåãã§ããã (5) 第ïŒæ¬ã¯ãåèš(4)ãšåæ§ã§ãããç·©è¡æ¶²äž
ã«ïŒŠïŒabâ²ïŒ2ã䜿çšããã ïŒabâ²ïŒ2åéäœããã¹ãŠã®å¹²æžãå®å šã«é€
å»ã§ããªãã€ãã®ã¯ïŒåã®ã¿ã§ããïŒ210581
â24ãâ27ïŒãèšåºçã«ã¯æ®ãã®å¹²æžã¯éèŠã§
ãªãã 第ïŒå³ã«åéïŒabâ²ïŒ2ã䜿çšããªãéœæ§è¡
æž 30è©Šæã®æ€å®çµæïŒPACIA察RIAïŒã瀺
ãïŒïœïŒ0.97ãïœïŒ0.79xïŒ16.2ïŒããããšæ¯
èŒããããã«åéïŒabâ²ïŒ2ã䜿çšããåãè¡
æž ã®æ€å®çµæã第ïŒå³ã«ç€ºãïŒïœïŒ0.99ãïœ
ïŒ0.85xïŒ0.2ïŒãçžé¢æ§ããã³åŸæã¯æãã
ã«æ¹åãããŠããã ïŒ æ¬çºæãããã«èª¬æãããããåŠåš 第16é±ã®
女åããã®è¡æž 99ã«ã€ããŠã¢ã«ãã¢ããšãã¿ã³
ãã¯ãåæããçµæã第ïŒè¡šã«ç€ºããè¡šäžã«ã
ããŠïŒ æ¬ã¯è©Šæçªå·ã§ããã æ¬ã¯åŠåš æéïŒé±ïŒã§ããã æ¬ã¯æŸå°å ç«æ€å®æ³ã«ãã枬å®ããã¢ã«ãã¢
ããšãã¿ã³ãã¯ã§ããã æ¬ã¯æ¬çºæã«ãããªãäºã€ã®ç²ååéæ€å®
ïŒD.EïŒã®çµæã®å¹³åå€ã§ããã æ¬ã¯ïŒ€ããã³ïŒ¥ãšåæ§ã«ã§ãããæ¬çºæã«åŸ
ã€ãŠåéïŒabâ²ïŒ2æçãå ããŠè¡ãªã€ãäºã€ã®
ç²ååéæ€å®ïŒG.HïŒã®çµæã®å¹³åå€ã§ããã æ¬çºæã«åŸã€ãŠïŒŠïŒabâ²ïŒ2åéäœã䜿çšããã
ãšã«ããæ¹åã¯æ¬¡ã®çµ±èšçæ°å€ã«ãã瀺ãã
ãïŒ RIAã«ããå¹³åå€ ïŒ34.6mgïŒml ïŒabâ²ïŒ2åéäœã䜿çšããPACIAã«ããå¹³å
å€ ïŒ34.6mgïŒml NRSã䜿çšãããïŒabâ²ïŒ2åéäœã䜿çšããª
ãPACIAã«ããå¹³åå€ ïŒ45.6mgïŒml
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
第ïŒå³ã¯16åã®è¡æž
ã®ããããã«ã€ããŠã®ïŒçš®
ã®æ€å®æäœã«ããç²åèšæ°çµæã瀺ãå³è¡šã§ã
ãã暪軞ã«è¡æž ã®è©Šæçªå·ãã瞊軞ã«èšæ°ã瀺
ãã第ïŒå³ã¯åéïŒabâ²ïŒ2ã䜿çšããªãéœæ§è¡æž
ã«ã€ããŠã®RIAãšPACIAãšã®çžé¢ã瀺ãå³è¡šã§
ããã第ïŒå³ã¯åãè¡æž ã«ã€ããŠåéïŒabâ²ïŒ2ã
䜿çšããå Žåã®åæ§ã®å³è¡šã§ããã
ã®æ€å®æäœã«ããç²åèšæ°çµæã瀺ãå³è¡šã§ã
ãã暪軞ã«è¡æž ã®è©Šæçªå·ãã瞊軞ã«èšæ°ã瀺
ãã第ïŒå³ã¯åéïŒabâ²ïŒ2ã䜿çšããªãéœæ§è¡æž
ã«ã€ããŠã®RIAãšPACIAãšã®çžé¢ã瀺ãå³è¡šã§
ããã第ïŒå³ã¯åãè¡æž ã«ã€ããŠåéïŒabâ²ïŒ2ã
䜿çšããå Žåã®åæ§ã®å³è¡šã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ç¬¬äžã®åç©çš®ããã®çç©äœæ¶²äžã®è¢«æ€å®æå
ãå ç«æ€å®ããã«ããããåèšçæç©äœæ¶²ãšãæ€
å®åå¿æ··åç©äžã®åèšè¢«æ€å®æåã«å¯ŸããŠå ç«ç
ã«ç¹ç°çã§ããã第äºã®åç©çš®ããã®ç¬¬äžã®å ç«
ã°ãããªã³ã®æåçµåæ§æçãšã®åå¿æ··åç©ã§ã
ã€ãŠãåèšç¬¬äžã®å ç«ã°ãããªã³å šäœããã³ãã®
(c)æçã¯å«ãŸãªãåå¿æ··åç©ã圢æããå ç«æ€
å®æ¹æ³ã«ãããŠã (a) åèšçç©äœæ¶²ãšãåèšè¢«æ€å®æåãšã¯çµåã
ãªããåèšç¬¬äžã®åç©çš®ããã®æäœãšã¯çµåã
ããåèšç¬¬äºã®åç©çš®ããã®ç¬¬äºã®å ç«ã°ãã
ãªã³ã®æåçµåæ§æçãšããæ··åãã (b) ããããŠåèšç¬¬äžã®å ç«ã°ãããªã³ã®æåçµ
åæ§æçãšåèšçç©æ¶²äœäžã«ååšããã®æçã«
察ããŠåå¿ããåèšç¬¬äžã®åç©çš®ããã®æäœãš
ã®åå¿ã«ãããæ€å®ãžã®å¹²æžããæžå°ãããã
ã㊠(c) 次ã«åèšç¬¬äžã®å ç«ã°ãããªã³ã®æåçµåæ§
æçãšåèšè¢«æ€å®æåãšã«ãã圢æãããè€å
äœã«ã€ããŠãåèšåå¿æ··åç©ãåæãã ããšãç¹åŸŽãšããå ç«æ€å®æ¹æ³ã ïŒ ç¬¬äºã®å ç«ã°ãããªã³ã®åèšæçãšããŠïŒŠ
ïŒabâ²ïŒ2æçã䜿ããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ ç¬¬äºã®å ç«ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçãåé
ãããŠè¡ãªããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ ç¬¬äºã®å ç«ã°ãããªã³ã®åèšæçãååŠçã«
åéãããŠè¡ãªããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ ç¬¬äºã®å ç«ã°ãããªã³ã®åèšæçãåºäœäžæº¶
æ§æ¯æäœãŸãã¯å¯æº¶æ§æ äœãšçµåãããŠè¡ãªãã
åé ïŒã«èšèŒã®æ¹æ³ã ïŒ å·¥çšïœã«ãããŠã第äžã®å ç«ã°ãããªã³ã®å
èšæçã被èŠãã埮现ç²åã§ãã€ãŠãåå¿æ··åç©
äžã®åèšè¢«æ€å®æåã®éã«åŸã€ãŠåéããç²å
ããåå¿æ··åç©äžã«å«æãããå·¥çš(c)ã«ãããŠã
åèšè¢«æ€å®æåã®éãéåéç²åã®èšæ°ã«ãã枬
å®ãããããŠç¬¬äºã®å ç«ã°ãããªã³ã®åèšæçã¯
æ€å®ã®éãåå¿æ··åç©äžã«æº¶è§£ããŠååšãããå
é ïŒã«èšèŒã®æ¹æ³ã ïŒ ç¬¬äžã®å ç«ã°ãããªã³ã®åèšæçãšããŠIgG
ã®ïŒŠïŒabâ²ïŒ2æçã䜿ããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ ããè¡æž äžã®è¢«æ€å®æåãå ç«æ€å®ããã«ã
ããã (a) ïŒïŒããè¡æž ãšãïŒïŒãã以å€ã®åç©ã
ãã®ç¬¬äžã®å ç«ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçãæ
æãã埮现ç²åãšïŒ»ããã§åå¿æ··åç©ã¯ç¬¬äžã®
å ç«ã°ãããªã³å šäœããã³ãã®ïŒŠ(c)æçã¯å«ãŸ
ããããŠç¬¬äžã®å ç«ã°ãããªã³ã¯åå¿æ··åç©äž
ã®åèšè¢«æ€å®æåã«å¯ŸããŠå ç«ç¹ç°çã§ããã
ã®ãšãããïŒïŒåèšã®ãã以å€ã®åç©ããã®
第äºã®å ç«ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçãšïŒ»ãã
ã§åèšç¬¬äºã®å ç«ã°ãããªã³ã¯åèšè¢«æ€å®æå
ãšã¯éåå¿æ§ã§ãããåèšãã以å€ã®åç©ãã
ã®ç¬¬äžã®å ç«ã°ãããªã³ã®ïŒŠïŒabâ²ïŒ2æçã«å¯Ÿã
ãããã®æäœãšã¯åå¿æ§ã§ãããã®ãšãããš
ã®åå¿æ··åç©ã圢æãã (b) éåéç²åãèšæ°ããåŸãããèšæ°å€ãæ¢ç¥
æ¿åºŠã®åèšè¢«æ€å®æåãå«ãäžé£ã®æšæºçµæç©
ã«ã€ããŠåŸãããèšæ°å€ãšæ¯èŒããããšã«ãã€
ãŠãååšããåèšè¢«æ€å®æåã®éãæ€å®ãã åé ïŒã«èšèŒã®æ¹æ³ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8200189 | 1982-01-05 | ||
GB8200189 | 1982-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58146855A JPS58146855A (ja) | 1983-09-01 |
JPH0467150B2 true JPH0467150B2 (ja) | 1992-10-27 |
Family
ID=10527451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8483A Granted JPS58146855A (ja) | 1982-01-05 | 1983-01-05 | å ç«æ€å®æ³ |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0083869B1 (ja) |
JP (1) | JPS58146855A (ja) |
AU (1) | AU567486B2 (ja) |
CA (1) | CA1185175A (ja) |
DE (1) | DE3266967D1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0101228B1 (en) * | 1982-08-06 | 1986-10-08 | International Institute Of Cellular And Molecular Pathology (Icp) | Particle agglutination assay of antigens |
ZA855031B (en) * | 1984-08-31 | 1986-02-26 | New York Blood Center Inc | Assay for simultaneous detection of antigen and antibody in given serum |
JPH0799372B2 (ja) * | 1985-07-13 | 1995-10-25 | å¯å£«ã¬ããªæ ªåŒäŒç€Ÿ | éå身åéåå¿çšéç¹ç°åå¿åžåå€ |
DE3715333A1 (de) * | 1987-05-08 | 1988-11-24 | Behringwerke Ag | Verfahren zur quantitativen bestimmung von serumproteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens |
DE3717401A1 (de) | 1987-05-23 | 1988-12-08 | Behringwerke Ag | Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel |
US4914040A (en) * | 1988-03-03 | 1990-04-03 | Boehringer Mannheim Gmbh | Reagent and method for determination of a polyvalent substance using an immunoaggregate |
IL102495A (en) * | 1992-07-14 | 1998-06-15 | Patchornik Avraham | Universal standard reagents, method of preparing same and use thereof |
JP4897429B2 (ja) * | 2006-10-23 | 2012-03-14 | æ ªåŒäŒç€ŸããŒã¬ ãã£ã«ã¿ãŒã·ã¹ãã 㺠| èžçºçæåŠçè£ çœ® |
ES2609280T3 (es) | 2007-08-23 | 2017-04-19 | Lsi Medience Corporation | Inhibidor de reacción no especÃfica |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS579723A (en) * | 1980-06-20 | 1982-01-19 | Mitsubishi Chem Ind Ltd | Stabilizing agent for immunological reaction and measuring method of antigen-antibody reaction |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4184849A (en) * | 1977-12-05 | 1980-01-22 | Technicon Instruments Corporation | Mixed agglutination |
GB2013211B (en) * | 1978-01-26 | 1982-06-30 | Technicon Instr | Immunoassays using f(ab')2 fragments |
AU543007B2 (en) * | 1980-04-15 | 1985-03-28 | Technicon Instruments Corportion | Agglutination immunoassay |
EP0051985B2 (en) * | 1980-11-07 | 1989-12-27 | International Institute Of Cellular And Molecular Pathology (Icp) | Immunoassay of proteins |
AU557731B2 (en) * | 1981-03-05 | 1987-01-08 | Westinghouse Electric Corporation | Catalytic gas turbine combustor |
SE461726B (sv) * | 1989-02-06 | 1990-03-19 | Rolf Arne Larsson | Anordning foer fasthaallning av knivblad foer skaerning av en pappersbana |
-
1982
- 1982-12-23 EP EP19820306917 patent/EP0083869B1/en not_active Expired
- 1982-12-23 DE DE8282306917T patent/DE3266967D1/de not_active Expired
-
1983
- 1983-01-04 CA CA000418851A patent/CA1185175A/en not_active Expired
- 1983-01-05 JP JP8483A patent/JPS58146855A/ja active Granted
- 1983-01-05 AU AU10036/83A patent/AU567486B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS579723A (en) * | 1980-06-20 | 1982-01-19 | Mitsubishi Chem Ind Ltd | Stabilizing agent for immunological reaction and measuring method of antigen-antibody reaction |
Also Published As
Publication number | Publication date |
---|---|
DE3266967D1 (en) | 1985-11-21 |
JPS58146855A (ja) | 1983-09-01 |
CA1185175A (en) | 1985-04-09 |
AU1003683A (en) | 1983-07-14 |
EP0083869A1 (en) | 1983-07-20 |
EP0083869B1 (en) | 1985-10-16 |
AU567486B2 (en) | 1987-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cambiaso et al. | Particle counting immunoassay (PACIA). I. A general method for the determination of antibodies, antigens, and haptens | |
US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
JPS60256057A (ja) | å ç«åŠç枬å®æ³ | |
US4427781A (en) | Particle agglutination immunoassay with agglutinator for determining haptens; PACIA | |
JPH0616044B2 (ja) | å ç«åŠçã©ããã¯ã¹åéæ³ | |
JPH0467150B2 (ja) | ||
AU657595B2 (en) | A method for the determination of antigens or antibodies in the presence of an immune complex | |
EP0485377B1 (en) | Solid phase immuno-assay with labelled conjugate | |
US4900684A (en) | CEA immunoassay free of human anti-mouse antibody false positives | |
JPS6215464A (ja) | éå身åéåå¿çšéç¹ç°åå¿åžåå€ | |
JP4413371B2 (ja) | ïœïœã®æž¬å®æ¹æ³åã³ãã®è©Šè¬ | |
JPH0230667B2 (ja) | ||
JPH04329357A (ja) | å ç«åŠç枬å®æ¹æ³ | |
JPH0712818A (ja) | å ç«åŠçæ€åºæ¹æ³ | |
US4946796A (en) | Method of immunoassay | |
JP4433642B2 (ja) | éç¹ç°åå¿ãæå¶ããã€ã ãã¢ãã»ã€æ³ | |
Mandal et al. | Factitiously elevated total triiodothyronine in a euthyroid patient with multiple myeloma | |
JPH0454905B2 (ja) | ||
JP3598701B2 (ja) | äžæº¶æ§æ äœãçšããå ç«ååŠç枬å®æ¹æ³ | |
EP1010980A1 (en) | Immunoassay of proteins | |
JPH08327629A (ja) | æ€äœååŠçæ¹æ³ | |
JPH0949840A (ja) | å ç«æž¬å®çšè©Šè¬åã³å ç«æž¬å®æ³ | |
Wikman-Coffelt et al. | Radioimmunoassay method for analysis of ethylcarbamate in wine | |
WO2018074467A1 (ja) | å ç«åŠç枬å®æ¹æ³ããã³æž¬å®è©Šè¬ | |
JPS6036966A (ja) | ãªãŠããå å枬å®çšã©ããã¯ã¹è©Šè¬ |